A new treatment that involves growing a patient's immune cells and then infusing them back into their body has shown promise for people with the rare blood disorder aplastic anemia. Results from the Phase 1 trial, led by Professor Ghulam Mufti, provide the first evidence that autologous regulatory T-cell therapy is feasible and safe in people with aplastic anemia and may have clinical benefit.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗